Commonwealth Diagnostics International, Inc.

Commonwealth Diagnostics International, Inc. is revolutionizing functional GI diagnostics with its range of non-invasive at-home hydrogen and methane breath tests. Founded in 2015 in Salem, Mass., CDI operates out of its CLIA-certified laboratory and as an FDA-registered, ISO 13485-certified medical device manufacturer, distinguishing itself as a trusted provider in the Health Care industry. CDI's breath tests aid in the diagnosis and treatment of a variety of gastrointestinal ailments, including Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), fructose malabsorption, lactose malabsorption, and sucrose malabsorption. The company's patient-centric approach prioritizes ease of use, speed, and safety for patients, ultimately supporting practitioners in achieving meaningful GI health outcomes. Despite having no recent disclosed investments, CDI's innovative solutions and patient-focused strategies position it as a compelling prospect in the functional GI diagnostics sector.